M1 Kliniken AG
- WKN: A0STSQ
- ISIN: DE000A0STSQ8
- Land: Deutschland
Nachricht vom 10.09.2018 | 18:23
M1 Kliniken AG: M1 Kliniken AG decides to implement a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments
M1 Kliniken AG / Key word(s): Corporate Action/Capital Increase
The Management Board of M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) today decided to increase the company's share capital by up to 10% against cash contributions on the basis of the authorization granted by the Annual General Meeting on July 10,2018 by partially utilizing the authorized capital 2018. The Supervisory Board has approved the Management Board's decision.
The share capital of the company is to be increased - by the partial utilization of the authorized capital 2018 of currently EUR 16,500,000.00 - by issuing up to 1,650,000 bearer shares to a total share capital of up to EUR 18,150,000.00. The new shares are to be eligible for dividends as of January 1,2018 and are to be offered to institutional investors by means of a placement procedure in accordance with the exemption provisions for private placements without a prospectus and included in the existing listing of the company's shares. The placement price will not be significantly lower than the market price.
The final placement volume and the placement share price will be determined by the Management Board, with the approval of the Supervisory Board, after the placement procedure has been completed and will be announced in a separate ad hoc announcement.
M1 Kliniken AG intends to use the proceeds from the capital increase to finance its expansion into new medical indications as well as the opening of additional M1-locations in Germany and abroad.
M1 Kliniken AG
The Board of Directors
About M1 Kliniken AG
M1 Kliniken AG is the leading private provider of health care services in the field of beauty medicine in Germany. In the field of aesthetic and surgical treatments, the Group offers products and services of the highest quality standards. Under the brand names "M1 Med Beauty" and "M1 Dental", a network of currently 20 ambulatory specialist centres for beauty treatments and a surgical clinic is operated. With six operating theatres and 35 beds, the M1 Schlossklinik Berlin is one of the largest and most modern facilities of ist kind in Europe. The Group also markets high-quality products to doctors, pharmacies and wholesalers.
The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.
In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.
In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to "qualified investors" within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.
Patrick Brenske, Management Board
|Company:||M1 Kliniken AG|
|Grünauer Straße 5|
|Phone:||+49 (0)30 347 47 44 14|
|Fax:||+49 (0)30 347 47 44 17|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart, Tradegate Exchange|
|End of Announcement||DGAP News Service|
M1 Kliniken AG: Successfully conducts the annu ...
M1 Kliniken AG: M1 Kliniken AG acquires 48 % o ...
M1 Kliniken AG: acquires ca. 48 % of the share ...
M1 Kliniken AG: Publishes consolidated financi ...
M1 Kliniken AG: Supervisory Board adopts the a ...
Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv
Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.
Der AKTIONÄR News
12. August 20:39 Dow Jones & Co geben wieder Gas: Tesla, Apple und Microsoft die ...
12. August 20:00 10.000 Euro für Sie – EXKLUSIV: 100 % mit dem Optionsschein-Paket
12. August 15:03 TUI: Weitere Milliarden vom Staat fließen
12. August 14:36 Nano One nach der Verzehnfachung: Neuer „Geheim-Deal“ beflügelt
News im Fokus
E.ON SE: E.ON trotz Covid-19-Effekten mit robustem Halbjahresergebnis
12. August 2020, 07:00
Webcast Q2 Results 2020
14. August 2020
Original-Research: Schweizer Electronic AG (von Montega AG): Halten
12. August 2020